Only BMP-2 (Infuse® bone graft) and BMP-7 (OP-1 putty®), also known as osteogenic protein 1 (OP-1), have been approved by the FDA for the treatment of very specific bone fractures that exhibit delayed or incomplete healing. The gene discussed is BMP7; the disease is bone fracture.